Showing 541 - 560 results of 6,579 for search '(( significant decrease decrease ) OR ( significant ((17 decrease) OR (a decrease)) ))~', query time: 0.57s Refine Results
  1. 541

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, the respective treatment counts for anti-VEGF, STTA, MA-PC, PPV, and total treatments (mean ± standard deviation) in the year before surgery were 3.0 ± 1.4, 0.1 ± 0.3, 0.8 ± 1.0, 0.1 ± 0.3, and 4.0 ± 2.1, respectively. These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”
  2. 542
  3. 543
  4. 544

    Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Regarding the mean number of treatments in the recurrence group, anti-VEGF, STTA, MA-PC, PPV, and total treatment counts in the year before surgery were 3.0 ± 1.4, 0.1 ± 0.3, 0.8 ± 1.0, 0.1 ± 0.3, and 4.0 ± 2.1, respectively. These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”
  5. 545
  6. 546
  7. 547
  8. 548
  9. 549
  10. 550
  11. 551
  12. 552
  13. 553
  14. 554
  15. 555
  16. 556
  17. 557
  18. 558
  19. 559
  20. 560